Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Arora on the Evolving Treatment Landscape in Multiple Myeloma

September 11th 2020

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.

Ixazomib Triplet Fails to Meet Primary End Point of PFS in Myeloma, Despite Improvement

September 11th 2020

Although the addition of ixazomib to lenalidomide and dexamethasone showed an improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, it was not determined to be of statistical significance.

Building on BCMA-Directed Therapies in Multiple Myeloma

September 10th 2020

Luciano J. Costa, MD, PhD, discusses emerging data regarding the use of BCMA-directed bispecific antibodies and antibody-drug conjugates in multiple myeloma.

CLR 131 Elicits Clinically Meaningful Responses in Triple-Class Refractory Myeloma

September 9th 2020

The first-in-class radioiodinated phospholipid drug conjugate CLR 131 elicited a clinically meaningful overall response rate of 40% in patients with triple-class refractory multiple myeloma who received a total administered dose of 60 mCi or greater.

Braunstein Reflects on the Rise of Quadruplet Therapies in Multiple Myeloma

September 8th 2020

Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment settings presented during the 2020 ASCO Virtual Scientific Program.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

September 8th 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma

September 8th 2020

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 3rd 2020

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

September 2nd 2020

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma.

GMMG-CONCEPT Trial Homes in on High-Risk Patients With Multiple Myeloma

September 1st 2020

Katja Weisel, MD, explains the rationale for the GMMG-CONCEPT trial, details the key interim findings, and provides foresight on future milestones in the field of multiple myeloma.

Dr. Richard on the Evolving Armamentarium in Multiple Myeloma

September 1st 2020

Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.

Subcutaneous Daratumumab in Myeloma Does Not Require Dose Individualization Based on Body Weight

September 1st 2020

The overall response rates with subcutaneous daratumumab proved to be similar to that of the intravenous formulation of the drug irrespective of body weight.

Among a Myriad of Treatment Options, Questions Remain in Newly Diagnosed Myeloma

August 31st 2020

Shambavi Richard, MD, discusses pivotal data in the multiple myeloma paradigm, as well as remaining questions that future research efforts should aim to address.

Dr. Richter on the Utility of Isatuximab in Relapsed/Refractory Myeloma

August 31st 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

FDA Grants Priority Review to Melphalan Flufenamide for Triple-Class Refractory Myeloma

August 31st 2020

The FDA has granted a priority review to a new drug application for melphalan flufenamide for use in combination with dexamethasone in adult patients with multiple myeloma whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody.

Novel Therapies Move Through the Relapsed/Refractory Myeloma Pipeline

August 28th 2020

Ajai Chari, MD, discusses the recent approval of belantamab mafodotin in relapsed/refractory multiple myeloma and other emerging agents under exploration in the space.

Belantamab Mafodotin Approved in Europe for Relapsed/Refractory Multiple Myeloma

August 27th 2020

The European Commission has approved belantamab mafodotin-blmf for the treatment of adult patients with multiple myeloma who have received at least 4 previous therapies, whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody, and who have progressed on their last therapy.

Personalized Approach Is Needed for Transplant-Ineligible Multiple Myeloma

August 27th 2020

Smith Giri, MD, MHS, discusses the options available for transplant-ineligible patients with myeloma, the factors to consider to personalize treatment, and future directions in the field.

Clinical Data Establish Role of Triplet Therapies in Relapsed Multiple Myeloma

August 24th 2020

Shagun D. Arora, MD, discusses findings from the phase 3 CANDOR, ICARIA-MM, and IKEMA studies which solidified the role of triplet regimens versus doublets in the relapsed/refractory multiple myeloma treatment landscape.

Questions Remain as CAR T-Cell Therapy Prepares to Transform Relapsed/Refractory Myeloma Treatment

August 24th 2020

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.